Posts by: Carolina Henriques

Carolina Henriques

Carolina holds a BSc in Anthropology and a MSc in Urban Studies., and brings her interdisciplinary skills to her writing on a range of different topics in science, research and advocacy news.

June 5, 2017June 5, 2017

EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

News

The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), used in the treatment ... Read more

May 22, 2017May 22, 2017

Learning Sessions Help Rheumatologists Take Better Care of RA Patients, Study Says

News

Group-based quality improvement sessions, based on the recommended “treat to target” (TTT) approach, can help rheumatologists improve the quality of their care for rheumatoid arthritis (RA) patients, a recent ... Read more

April 28, 2017April 28, 2017

Phase 3 Trial of Can-Fite’s Piclidenoson for Treating RA Is Underway

News

Can-Fite BioPharma’s Phase 3 ACRobat clinical trial protocol was approved by Barzilai Medical Center’s Institutional Review Board (IRB) and patient enrollment is now ready to begin. The study will ... Read more

April 19, 2017April 19, 2017

Inmedix, Omegawave to Adapt Elite-athlete Tests to Rheumatoid Arthritis Diagnosis

News, rheumatoid arthritis

Inmedix and Omegawave will work together on medical applications of tests related to athletes’ performance, with one target being rheumatoid arthritis (RA). A key goal will be to enhance biomarker ... Read more

April 17, 2017April 19, 2017

FDA Asks More Information a Second Time on Baricitinib as Arthritis Therapy

News, rheumatoid arthritis

U.S. regulators want additional dosing- and safety-related information before they will approve Eli Lilly and Incyte‘s New Drug Application (NDA) request for the rheumatoid arthritis (RA) treatment baricitinib. It is the ... Read more

March 1, 2017March 1, 2017

Truxima, Biosimilar of Rituximab, Approved in Europe for RA and Certain Cancers

News, rheumatoid arthritis

The European Commission approved Truxima as a biosimilar of rituximab (sold under the brand name Rituxan in the U.S.) in the EU for all indications approved for rituximab, including rheumatoid ... Read more

February 22, 2017February 22, 2017

Pfizer Reports Positive Results for Xeljanz as RA Therapy, When Combined with Methotrexate

News, rheumatoid arthritis

Pfizer recently announced top-line results from its Phase 3b/4 trial evaluating Xeljanz (tofacitinib citrate) as a treatment for moderate-to-severe rheumatoid arthritis (RA). The trial demonstrates that Xeljanz is more effective ... Read more

February 17, 2017February 17, 2017

RA Patients Treated with Olumiant Show Improvements Compared to Humira, Placebo

News, rheumatoid arthritis

In a pivotal Phase 3 clinical trial, Olumiant (baricitinib) improved patients’ outcomes in the treatment of moderate-to-severe rheumatoid arthritis (RA), in comparison to Humira (adalimumab) and placebo, according to ... Read more

February 15, 2017February 15, 2017

European Commission OKs Marketing Olumiant Tablets for Adults with Active RA

News, rheumatoid arthritis

The European Commission has granted marketing authorization for Olumiant (baricitinib) 4 mg and 2 mg tablets for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who ... Read more

January 18, 2017January 18, 2017

Review Period for Eli Lilly’s RA Therapy Baricitinib Extended by FDA

News, rheumatoid arthritis

The U.S. Food and Drug Administration (FDA) has extended the review period for a new drug application (NDA) for Eli Lilly’s investigational treatment baricitinib for rheumatoid arthritis (RA). The announcement ... Read more

Pin It on Pinterest